CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.

Riether, Carsten; Schürch, Christian M.; Bührer, Elias D.; Hinterbrandner, Magdalena; Huguenin, Anne-Laure; Höpner, Sabine; Zlobec, Inti; Pabst, Thomas; Radpour, Ramin; Ochsenbein, Adrian F. (2017). CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. The Journal of experimental medicine, 214(2), pp. 359-380. Rockefeller Univ. Press 10.1084/jem.20152008

[img]
Preview
Text
jem.20152008.full.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-Share Alike (CC-BY-NC-SA).
After six months it is available under a Creative Commons License (Attribution–Noncommercial– Share Alike 4.0 International license

Download (4MB) | Preview

Aberrant proliferation, symmetric self-renewal, increased survival, and defective differentiation of malignant blasts are key oncogenic drivers in acute myeloid leukemia (AML). Stem cell gene signatures predict poor prognosis in AML patients; however, with few exceptions, these deregulated molecular pathways cannot be targeted therapeutically. In this study, we demonstrate that the TNF superfamily ligand-receptor pair CD70/CD27 is expressed on AML blasts and AML stem/progenitor cells. CD70/CD27 signaling in AML cells activates stem cell gene expression programs, including the Wnt pathway, and promotes symmetric cell divisions and proliferation. Soluble CD27, reflecting the extent of CD70/CD27 interactions in vivo, was significantly elevated in the sera of newly diagnosed AML patients and is a strong independent negative prognostic biomarker for overall survival. Blocking the CD70/CD27 interaction by mAb-induced asymmetric cell divisions and differentiation in AML blasts and AML stem/progenitor cells inhibited cell growth and colony formation and significantly prolonged survival in murine AML xenografts. Importantly, hematopoietic stem/progenitor cells from healthy BM donors express neither CD70 nor CD27 and were unaffected by blocking mAb treatment. Therefore, targeting CD70/CD27 signaling represents a promising therapeutic strategy for AML.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Translational Research Unit
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.)

UniBE Contributor:

Riether, Carsten; Schürch, Christian; Bührer, Elias; Höpner, Sabine; Zlobec, Inti; Pabst, Thomas; Radpour, Ramin and Ochsenbein, Adrian

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1540-9538

Publisher:

Rockefeller Univ. Press

Language:

English

Submitter:

Marianne Zahn

Date Deposited:

19 Jan 2017 11:16

Last Modified:

29 May 2018 10:56

Publisher DOI:

10.1084/jem.20152008

PubMed ID:

28031480

Additional Information:

C. Riether and C.M. Schürch contributed equally to this paper

BORIS DOI:

10.7892/boris.93819

URI:

https://boris.unibe.ch/id/eprint/93819

Actions (login required)

Edit item Edit item
Provide Feedback